{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T07:37:14Z","timestamp":1775029034120,"version":"3.50.1"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001779","name":"Monash University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001779","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT1197958"],"award-info":[{"award-number":["GNT1197958"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.bone.2026.117821","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T17:33:36Z","timestamp":1770312816000},"page":"117821","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Atypical femoral fracture with early PET\/CT changes from denosumab for metastatic breast cancer and transition from denosumab to zoledronic acid"],"prefix":"10.1016","volume":"206","author":[{"given":"Chelsea","family":"Tan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daphne","family":"Day","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace","family":"Man","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanh H.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter R.","family":"Ebeling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frances","family":"Milat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"35","key":"10.1016\/j.bone.2026.117821_bb0005","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.bone.2026.117821_bb0010","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/cncr.27789","article-title":"Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acid","volume":"119","author":"Cleeland","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.bone.2026.117821_bb0015","article-title":"Breast metastatic denosumab","author":"Cancer Institute NSW","year":"2024","journal-title":"eviQ"},{"issue":"1","key":"10.1016\/j.bone.2026.117821_bb0020","first-page":"447","article-title":"Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer","volume":"24","author":"Stopeck","year":"2016","journal-title":"Support Care Cancer"},{"issue":"1","key":"10.1016\/j.bone.2026.117821_bb0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jbmr.1998","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research","volume":"29","author":"Shane","year":"2014","journal-title":"J. Bone Miner. Res."},{"issue":"1","key":"10.1016\/j.bone.2026.117821_bb0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jbm4.10024","article-title":"Genetic risk factors for atypical femoral fractures (AFFs): a systematic review","volume":"2","author":"Nguyen","year":"2018","journal-title":"JBMR Plus"},{"issue":"4","key":"10.1016\/j.bone.2026.117821_bb0035","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/jbmr.2748","article-title":"Incidence and characteristics of atypical femoral fractures: clinical and geometrical data","volume":"31","author":"Mahjoub","year":"2016","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2026.117821_bb0040","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.bone.2015.10.016","article-title":"Assessment of femur geometrical parameters using EOS\u2122 imaging technology in patients with atypical femur fractures; preliminary results","volume":"83","author":"Morin","year":"2016","journal-title":"Bone"},{"issue":"19","key":"10.1016\/j.bone.2026.117821_bb0045","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1056\/NEJMc0910389","article-title":"Atypical femoral fractures and bisphosphonate use","volume":"362","author":"Girgis","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bone.2026.117821_bb0050","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3109\/17453674.2015.1004149","article-title":"Risk of atypical femoral fracture during and after bisphosphonate use","volume":"86","author":"Schilcher","year":"2015","journal-title":"Acta Orthop."},{"key":"10.1016\/j.bone.2026.117821_bb0055","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.bone.2016.01.002","article-title":"The association of race\/ethnicity and risk of atypical femur fracture among older women receiving oral bisphosphonate therapy","volume":"85","author":"Lo","year":"2016","journal-title":"Bone"},{"key":"10.1016\/j.bone.2026.117821_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2020.115319","article-title":"Asian ethnicity is associated with atypical femur fractures in an Australian population study","volume":"135","author":"Nguyen","year":"2020","journal-title":"Bone"},{"issue":"8","key":"10.1016\/j.bone.2026.117821_bb0065","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1056\/NEJMoa1916525","article-title":"Atypical femur fracture risk versus fragility fracture prevention with bisphosphonates","volume":"383","author":"Black","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2026.117821_bb0070","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-71024-y","article-title":"Comparison of bone turnover suppression in atypical femoral fractures and osteoporotic hip fractures","volume":"14","author":"Ahn","year":"2024","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.bone.2026.117821_bb0075","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1002\/jbmr.1550","article-title":"Incidence and demography of femur fractures with and without atypical features","volume":"27","author":"Feldstein","year":"2012","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2026.117821_bb0080","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1001\/archinternmed.2012.1796","article-title":"Increasing occurrence of atypical femoral fractures associated with bisphosphonate use","volume":"172","author":"Meier","year":"2012","journal-title":"Arch. Intern. Med."},{"issue":"7","key":"10.1016\/j.bone.2026.117821_bb0085","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"10","key":"10.1016\/j.bone.2026.117821_bb0090","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10681","article-title":"Incidence of atypical femoral fractures in patients on osteoporosis therapy \u2013 a registry-based cohort study","volume":"6","author":"Everts-Graber","year":"2022","journal-title":"JBMR Plus"},{"issue":"1","key":"10.1016\/j.bone.2026.117821_bb0095","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-019-6236-6","article-title":"Atypical femoral fracture in patients with bone metastasis receiving denosumab therapy: a retrospective study and systematic review","volume":"19","author":"Takahashi","year":"2019","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.bone.2026.117821_bb0100","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1634\/theoncologist.2016-0192","article-title":"Retrospective review of atypical femoral fracture in metastatic bone disease patients receiving denosumab therapy","volume":"22","author":"Yang","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.bone.2026.117821_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2020.100301","article-title":"Incidence of atypical femoral fractures in the treatment of bone metastasis: an alert report","volume":"23","author":"Kaku","year":"2020","journal-title":"J. Bone Oncol."},{"issue":"4","key":"10.1016\/j.bone.2026.117821_bb0110","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s12282-016-0746-8","article-title":"Atypical femoral fracture after receiving antiresorptive drugs in breast cancer patients with bone metastasis","volume":"24","author":"Ota","year":"2017","journal-title":"Breast Cancer"},{"issue":"4","key":"10.1016\/j.bone.2026.117821_bb0115","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pky062","article-title":"Change in survival in metastatic breast cancer with treatment advances: meta-analysis and systematic review","volume":"2","author":"Caswell-Jin","year":"2018","journal-title":"JNCI Cancer Spectr."},{"issue":"2","key":"10.1016\/j.bone.2026.117821_bb0120","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1148\/radiol.13122691","article-title":"Detection of prefracture hip lesions in atypical subtrochanteric fracture with dual-energy x-ray absorptiometry images","volume":"270","author":"Kim","year":"2014","journal-title":"Radiology"},{"issue":"7","key":"10.1016\/j.bone.2026.117821_bb0125","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10749","article-title":"Prevalence of precursory signs of atypical femoral fractures in patients receiving bone-modifying agents for bone metastases: a cross-sectional study","volume":"7","author":"Kaku","year":"2023","journal-title":"JBMR Plus"},{"issue":"3","key":"10.1016\/j.bone.2026.117821_bb0130","doi-asserted-by":"crossref","first-page":"737","DOI":"10.4172\/2165-7920.1000737","article-title":"Atypical femoral fracture in a patient with metastatic breast cancer during denosumab cancer","volume":"6","author":"Ohnaru","year":"2016","journal-title":"J. Clin. Case Rep."},{"issue":"4","key":"10.1016\/j.bone.2026.117821_bb0135","doi-asserted-by":"crossref","first-page":"659","DOI":"10.4055\/cios22052","article-title":"Importance of whole-body scintigraphy or positron emission tomography for early detection of femoral lesions in breast cancer patients treated with bisphosphonates","volume":"15","author":"Cha","year":"2023","journal-title":"Clin. Orthop. Surg."},{"issue":"3","key":"10.1016\/j.bone.2026.117821_bb0140","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/ans.12018","article-title":"Burden of bisphosphonate-associated femoral fractures","volume":"83","author":"Shkolnikova","year":"2013","journal-title":"ANZ J. Surg."},{"issue":"6","key":"10.1016\/j.bone.2026.117821_bb0145","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.2214\/AJR.09.3588","article-title":"Subtrochanteric femoral fractures in patients receiving long-term alendronate therapy: imaging features","volume":"194","author":"Chan","year":"2010","journal-title":"AJR Am. J. Roentgenol."},{"key":"10.1016\/j.bone.2026.117821_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2023.100478","article-title":"Multicenter study on atypical femoral fractures in patients with bone metastases taking bone-modifying agents","volume":"40","author":"Fukui","year":"2023","journal-title":"J. Bone Oncol."},{"issue":"11","key":"10.1016\/j.bone.2026.117821_bb0155","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1002\/jbmr.253","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research","volume":"25","author":"Shane","year":"2010","journal-title":"J. Bone Miner. Res."},{"issue":"5","key":"10.1016\/j.bone.2026.117821_bb0160","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1210\/clinem\/dgz295","article-title":"Medical management of patients after atypical femur fractures: a systematic review and recommendations from the European calcified tissue society","volume":"105","author":"van de Laarschot","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2026.117821_bb0165","doi-asserted-by":"crossref","DOI":"10.1186\/s12891-016-1086-8","article-title":"Management of atypical femoral fracture: a scoping review and comprehensive algorithm","volume":"17","author":"Toro","year":"2016","journal-title":"BMC Musculoskelet. Disord."},{"issue":"3","key":"10.1016\/j.bone.2026.117821_bb0170","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1302\/0301-620X.99B3.BJJ-2016-0276.R2","article-title":"Atypical femoral fractures related to bisphosphonate treatment: issues and controversies related to their surgical management","volume":"99-B","author":"Koh","year":"2017","journal-title":"Bone Joint J."},{"issue":"6","key":"10.1016\/j.bone.2026.117821_bb0175","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/BOT.0b013e31827240ae","article-title":"Surgical treatment improves clinical and functional outcomes for patients who sustain incomplete bisphosphonate-related femur fractures","volume":"27","author":"Egol","year":"2013","journal-title":"J. Orthop. Trauma"},{"issue":"1","key":"10.1016\/j.bone.2026.117821_bb0180","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3390\/jcm10010152","article-title":"Denosumab discontinuation and the rebound phenomenon: a narrative review","volume":"10","author":"Anastasilakis","year":"2021","journal-title":"J. Clin. Med."},{"issue":"5","key":"10.1016\/j.bone.2026.117821_bb0185","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.cell.2021.02.002","article-title":"Osteoclasts recycle via osteomorphs during RANKL-stimulated bone resorption","volume":"184","author":"McDonald","year":"2021","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.bone.2026.117821_bb0190","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1093\/jbmr\/zjae170","article-title":"The effects of denosumab on osteoclast precursors in postmenopausal women: a possible explanation for the overshoot phenomenon after discontinuation","volume":"40","author":"Schini","year":"2025","journal-title":"J. Bone Miner. Res."},{"issue":"4","key":"10.1016\/j.bone.2026.117821_bb0195","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1210\/jc.2010-1502","article-title":"Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass","volume":"96","author":"Bone","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2026.117821_bb0200","article-title":"Rebound-associated vertebral fractures after denosumab discontinuation in a lung cancer patient with bone metastases","volume":"16","author":"Dupont","year":"2022","journal-title":"Bone Rep."},{"issue":"2","key":"10.1016\/j.bone.2026.117821_bb0205","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.mayocpiqo.2019.02.003","article-title":"Rebound vertebral fractures in a patient with lung cancer after oncology-dose denosumab discontinuation: a cautionary tale","volume":"3","author":"Tyan","year":"2019","journal-title":"Mayo Clin. Proc. Innov. Qual. Outcomes"},{"key":"10.1016\/j.bone.2026.117821_bb0210","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1136\/annrheumdis-2024-eular.916","article-title":"Ab309 fracture risk following denosumab discontinuation in the oncologic population: incidence and risk factors","volume":"83","author":"Amigues","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bone.2026.117821_bb0215","article-title":"Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS","author":"Tsourdi","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"12","key":"10.1016\/j.bone.2026.117821_bb0220","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s00198-003-1508-y","article-title":"Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF)","volume":"14","author":"Fogelman","year":"2003","journal-title":"Osteoporos. Int."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328226000475?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328226000475?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T05:21:29Z","timestamp":1775020889000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328226000475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":44,"alternative-id":["S8756328226000475"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2026.117821","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Atypical femoral fracture with early PET\/CT changes from denosumab for metastatic breast cancer and transition from denosumab to zoledronic acid","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2026.117821","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"117821"}}